UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.87+1.77 (+6.30%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma gross margin
Gross margin is gross profit as a percentage of revenue.
UroGen Pharma's gross margin for the twelve months ending Jun 30, 2026 was 90.8%. For fiscal 2025 it was 88.7%, against 90.2% the year before. The highest annual figure on record is 100.0% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88.7% | −1.5 |
| FY2024 | Dec 31, 2024 | 90.2% | +1.5 |
| FY2023 | Dec 31, 2023 | 88.7% | +0.6 |
| FY2022 | Dec 31, 2022 | 88.1% | −1.2 |
| FY2021 | Dec 31, 2021 | 89.3% | −2.2 |
| FY2020 | Dec 31, 2020 | 91.4% | −8.6 |
| FY2019 | Dec 31, 2019 | 100.0% | +159.8 |
| FY2018 | Dec 31, 2018 | -59.8% | −152.5 |
| FY2017 | Dec 31, 2017 | 92.6% | −7.2 |
| FY2016 | Dec 31, 2016 | 99.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 90.9% | +5.6 |
| Q1 FY2026 | Mar 31, 2026 | 91.9% | +3.4 |
| Q4 FY2025 | Dec 31, 2025 | 91.3% | +1.4 |
| Q3 FY2025 | Sep 30, 2025 | 88.1% | −2.2 |
| Q2 FY2025 | Jun 30, 2025 | 85.3% | −4.5 |
| Q1 FY2025 | Mar 31, 2025 | 88.5% | −2.3 |
| Q4 FY2024 | Dec 31, 2024 | 89.9% | −0.3 |
| Q3 FY2024 | Sep 30, 2024 | 90.3% | +1.6 |
| Q2 FY2024 | Jun 30, 2024 | 89.8% | +1.4 |
| Q1 FY2024 | Mar 31, 2024 | 90.8% | +4.0 |
| Q4 FY2023 | Dec 31, 2023 | 90.3% | +2.8 |
| Q3 FY2023 | Sep 30, 2023 | 88.6% | +1.2 |
| Q2 FY2023 | Jun 30, 2023 | 88.4% | −0.4 |
| Q1 FY2023 | Mar 31, 2023 | 86.8% | −1.9 |
| Q4 FY2022 | Dec 31, 2022 | 87.5% | −2.7 |
| Q3 FY2022 | Sep 30, 2022 | 87.5% | −1.6 |
| Q2 FY2022 | Jun 30, 2022 | 88.9% | −0.2 |
| Q1 FY2022 | Mar 31, 2022 | 88.8% | +0.7 |
| Q4 FY2021 | Dec 31, 2021 | 90.2% | −1.6 |
| Q3 FY2021 | Sep 30, 2021 | 89.0% | −2.0 |
| Q2 FY2021 | Jun 30, 2021 | 89.1% | +2.0 |
| Q1 FY2021 | Mar 31, 2021 | 88.0% | −12.0 |
| Q4 FY2020 | Dec 31, 2020 | 91.8% | +364.6 |
| Q3 FY2020 | Sep 30, 2020 | 91.1% | +78.4 |
| Q2 FY2020 | Jun 30, 2020 | 87.1% | +76.5 |
| Q2 FY2019 | Jun 30, 2019 | 100.0% | +87.8 |
| Q3 FY2018 | Sep 30, 2018 | -272.8% | −369.0 |
| Q2 FY2018 | Jun 30, 2018 | 12.6% | +7.4 |
| Q1 FY2018 | Mar 31, 2018 | 10.6% | – |
| Q4 FY2017 | Dec 31, 2017 | 12.2% | – |
| Q3 FY2017 | Sep 30, 2017 | 96.2% | – |
| Q1 FY2017 | Mar 31, 2017 | 5.3% | – |
See a number that looks wrong?